Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Research Article

Decreased expression of IGFBP7 was a poor prognosis predictor for gastric cancer patients

Authors: Long Liu, Zhihui Yang, Weixing Zhang, Bing Yan, Qunhao Gu, Jianpeng Jiao, Xiaoqiang Yue

Published in: Tumor Biology | Issue 9/2014

Login to get access

Abstract

Increasing evidence indicated that insulin-like growth factor binding protein 7 (IGFBP7) was regarded as a potential tumor suppressor in various human cancers, but its role in gastric cancer is still largely unknown. In the present study, we performed a retrospective study which includes 247 gastric cancer patients. Among them, the IGFBP7 expression was detected by qRT-PCR in 138 cases of gastric cancer and adjacent non-tumor tissues and was further correlated with the expression of p53, Ki-67, and the clinicopathologic features. The results indicated that both IGFBP7 mRNA and protein in gastric cancer tissues were significantly lower than those in the adjacent non-tumor tissues. Additionally, the expression of IGFBP7 was correlated with the depth of invasion, lymph node metastasis, and TNM stage. Interestingly, the expression of IGFBP7 was negatively associated with Ki-67 (r = −0.227, P < 0.001) but positively associated with p53 (r = 0.140, P = 0.028). Univariate analysis showed that low expression of IGFBP7 was associated with poor prognosis (P < 0.001), and multivariate analysis showed that IGFBP7 (HR = 1.87; 95 % CI 1.65–2.17), distant metastasis (HR = 2.68; 95 % CI 1.58–4.56), and tumor size (HR = 1.45; 95 % CI 0.90–2.32) were independent prognostic factors for gastric cancer patients. These results demonstrated that IGFBP7 was downregulated in gastric cancer, and its low expression was potentially correlated with increased cancer cell proliferation and could be used to predicate poor prognosis in these patients.
Literature
1.
Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467–77.CrossRefPubMed
2.
3.
Liu D, Zhang Z, Kong CZ. High FOXM1 expression was associated with bladder carcinogenesis. Tumour Biol. 2013;34:1131–8.CrossRefPubMed
4.
Hu BS, Hu H, Zhu CY, et al. Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol. 2013;34:515–20.CrossRefPubMed
5.
Sun DZ, Liu L, Jiao JP, et al. Syndrome characteristics of traditional Chinese medicine: summary of a clinical survey in 767 patients with gastric cancer. J Chin Integr Med. 2010;4:332–40.CrossRef
6.
Wang WJ. Enhancing the treatment of metabolic syndrome with integrative medicine. J Chin Integr Med. 2013;11:153–6.CrossRef
7.
Burger AM, Leyland-Jones B, Banerjee K, et al. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer. Eur J Cancer. 2005;41:1515–27.CrossRefPubMed
8.
Wilson HM, Birnbaum RS, Poot M, et al. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ. 2002;13:205–13.PubMed
9.
Walker GE, Antoniono RJ, Ross HJ, et al. Neuroendocrine-like differentiation of non-small cell lung carcinoma cells: regulation by cAMP and the interaction of mac25/IGFBPrP1 and 25.1. Oncogene. 2006;25:1943–54.CrossRefPubMed
10.
Sato Y, Chen Z, Miyazaki K. Strong suppression of tumor growth by insulin-like growth factor-binding protein-related protein 1/tumor-derived cell adhesion factor/mac25. Cancer Sci. 2007;98:1055–63.CrossRefPubMed
11.
Wajapeyee N, Serra RW, Zhu X, et al. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 2008;132:363–74.PubMedCentralCrossRefPubMed
12.
Suzuki H, Igarashi S, Nojima M, et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis. 2010;31:342–9.CrossRefPubMed
13.
Ruan W, Xu E, Xu F, et al. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther. 2007;6:354–9.CrossRefPubMed
14.
Burger AM, Zhang X, Li H, et al. Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas. Oncogene. 1998;16:2459–67.CrossRefPubMed
15.
Landberg G, Ostlund H, Nielsen NH, et al. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Oncogene. 2001;20:3497–505.CrossRefPubMed
16.
Tomimaru Y, Eguchi H, Wada H, et al. IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma. Int J Cancer. 2011;2:319–27.
17.
Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2009. p. 117–26.
18.
Sarela AI, Verbeke CS, Ramsdale J, et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86:886–92.PubMedCentralCrossRefPubMed
19.
Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 2003;98:474–83.CrossRefPubMed
20.
Yamasawa K, Nio Y, Dong M, et al. Clinicopathological significance of abnormalities in Gadd45 expression and its relationship to p53 in human pancreatic cancer. Clin Cancer Res. 2002;8:2563–9.PubMed
21.
Yamamoto S, Tomita Y, Hoshida Y, et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:2846–50.CrossRefPubMed
22.
Oh Y, Nagalla SR, Yamanaka Y, et al. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem. 1996;271:30322–5.CrossRefPubMed
23.
Yamanaka Y, Wilson EM, Rosenfeld RG, et al. Inhibition of insulin receptor activation by insulin-like growth factor binding proteins. J Biol Chem. 1997;272:30729–34.CrossRefPubMed
24.
Chen Y, Pacyna-Gengelbach M, Ye F, et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol. 2007;211:431–8.CrossRefPubMed
25.
Ruan WJ, Lin J, Xu EP, et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B. 2006;7:929–32.PubMedCentralCrossRefPubMed
26.
Sprenger CC, Damon SE, Hwa V, et al. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) is a potential tumor suppressor protein for prostate cancer. Cancer Res. 1999;59:2370–5.PubMed
27.
Vizioli MG, Sensi M, Miranda C, et al. IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene. 2010;29:3835–44.CrossRefPubMed
28.
Amemiya Y, Yang W, Benatar T, et al. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Breast Cancer Res Treat. 2011;126:373–84.CrossRefPubMed
29.
Sprenger CC, Vail ME, Evans K, et al. Overexpression of insulin-like growth factor binding protein-related protein-1(IGFBP-rP1/mac25) in the M12 prostate cancer cell line alters tumor growth by a delay in G1 and cyclin A associated apoptosis. Oncogene. 2002;21:140–7.CrossRefPubMed
30.
Benatar T, Yang W, Amemiya Y, et al. IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways. Breast Cancer Res Treat. 2012;133:563–73.CrossRefPubMed
31.
Seth A, Benatar T, Amemiya Y,et al. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors. Hugo J. 2010;4:110–1.
32.
Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 2007;30:1359–67.PubMed
33.
Stanton KJ, Sidner RA, Miller GA, et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg. 2003;186:486–92.CrossRefPubMed
Metadata
Title
Decreased expression of IGFBP7 was a poor prognosis predictor for gastric cancer patients
Authors
Long Liu
Zhihui Yang
Weixing Zhang
Bing Yan
Qunhao Gu
Jianpeng Jiao
Xiaoqiang Yue
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2160-1

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Review

Relevance of miR-21 in HIV and non-HIV-related lymphomas

Research Article

The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas

Research Article

Increased MTHFD2 expression is associated with poor prognosis in breast cancer

Editorial

Long noncoding RNA HMlincRNA717 and AC130710 have been officially named as gastric cancer associated transcript 2 (GACAT2) and GACAT3, respectively

Research Commentary

Letter regarding Chen et al. entitled “A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma”

Research Article

Seminal plasma protein in renal cell carcinoma: expression of semenogelin I is a predictor for cancer progression and prognosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits